Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566993 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
A Phase 3 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 3
- Development phase
- 613
- Enrollment target
NCT02566993 is a Phase 3 study that has completed, run by PharmaMar. The registered enrollment target is 613 participants.
The verdict
NCT02566993, a Phase 3 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 613 participants
- Enrollment target
Study Summary
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Interventions
- DRUG Topotecan
- DRUG Cyclophosphamide (CTX)
- DRUG Lurbinectedin (PM01183)
- DRUG Doxorubicin (DOX)
- DRUG Vincristine (VCR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 613 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2020-02-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566993
The ClinicalTrials.gov registry entry for NCT02566993 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 613 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Topotecan is the first listed.
NCT02566993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02566993 about?
NCT02566993 is a clinical study titled "Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer". Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
What is the current status of trial NCT02566993?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 613 participants. The study started on 2016-08-30. Estimated completion is 2020-02-24.
What interventions are being tested in trial NCT02566993?
The interventions under investigation include: Topotecan (DRUG), Cyclophosphamide (CTX) (DRUG), Lurbinectedin (PM01183) (DRUG), Doxorubicin (DOX) (DRUG), Vincristine (VCR) (DRUG).
Who is sponsoring clinical trial NCT02566993?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.